Comment on: “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”

The original article was published

A Reply to this article was published

This is a preview of subscription content, log in to check access.


  1. 1.

    Ramakrishnan TCR, Kumaravelu S, Narayan SK, et al. Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke: results of two open-label, multicenter trials. Am J Cardiovasc Drugs. 2018;18(5):387–95.

    Article  Google Scholar 

  2. 2.

    Tang H, Foster NR, Grothey A, et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol. 2010;28:1936–41.

    Article  Google Scholar 

  3. 3.

    Arboix A, Alio J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2010;6:150–61.

    Article  Google Scholar 

  4. 4.

    Haley EC, Thompson JLP, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41:707–11.

    CAS  Article  Google Scholar 

  5. 5.

    Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099–107.

    CAS  Article  Google Scholar 

  6. 6.

    Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14:368–76.

    CAS  Article  Google Scholar 

  7. 7.

    Campbell BC, et al. Tenecteplase versus Alteplase before thrombectomy for ischaemic stroke. N Engl J Med. 2018;378:1573–82.

    CAS  Article  Google Scholar 

  8. 8.

    Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16:781–8.

    CAS  Article  Google Scholar 

  9. 9.

    Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–110.

    Article  Google Scholar 

  10. 10.

    Hill MD et al. A randomized controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion (TEMPO-2). Accessed 27 Sep 2018.

  11. 11.

    Spratt N et al. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial. Accessed 27 Sep 2018.

  12. 12.

    Mathiesen EB et al. Tenecteplase in wake-up ischaemic stroke trial (TWIST). Accessed 27 Sep 2018.

  13. 13.

    Muir K et al. Alteplase–tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST-2). Accessed 27 Sep 2018.

  14. 14.

    Campbell B, Sallaberger M et al. Determining the optimal dose of tenecteplase before endovascular therapy for ischaemic stroke (EXTEND-IA TNK Part 2). Accessed 27 Sep 2018.

Download references

Author information



Corresponding author

Correspondence to Prashant B. Rana.

Ethics declarations


No sources of funding were used to assist with the preparation of this manuscript.

Conflicts of interest

Prashant Rana, Nilan Jacob, Tomson Toms, and Shraddha Bhure are employees of Boehringer Ingelheim India Pvt. Ltd., and have no additional conflicts of interest that might be relevant to the content of this letter.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rana, P.B., Jacob, N.T., Toms, T. et al. Comment on: “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”. Am J Cardiovasc Drugs 19, 219–221 (2019).

Download citation